论文部分内容阅读
目的对比慢性肾脏病血液透析患者促红细胞生成素用药途径的疗效。方法按照随机分组原则,将168例慢性肾脏病血液透析患者分为静脉注射组和皮下注射组,每组84例,初始剂量为5900~6000 U/周,分为2次进行。连续治疗12周,之后监测患者的血红蛋白(Hb)、肾功能、血电解质以及丙氨酸氨基转移酶(ALT)等水平的变化情况。结果皮下注射组患者用药有效率为90.48%(76/84),静脉注射组为71.43%(60/84),两组比较差异有统计学意义(P<0.05)。结论慢性肾脏病血液透析患者应用皮下注射的方式治疗肾性贫血症状,疗效更佳。
Objective To compare the curative effect of erythropoietin on hemodialysis patients with chronic kidney disease. Methods According to the principle of randomization, 168 cases of chronic kidney disease hemodialysis patients were divided into intravenous injection group and subcutaneous injection group, 84 cases in each group, the initial dose was 5900 ~ 6000 U / week, divided into 2 times. After continuous treatment for 12 weeks, the changes of hemoglobin (Hb), renal function, serum electrolytes and ALT were monitored. Results The effective rate was 90.48% (76/84) in the subcutaneous injection group and 71.43% (60/84) in the intravenous injection group. There was significant difference between the two groups (P <0.05). Conclusion Chronic kidney disease patients with hemodialysis subcutaneous injection of renal anemia symptoms, better effect.